CRSP241108C60000
- 0.01
- -0.04-80.00%
CRISPR Therapeutics Newsroom
Morgan Stanley Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Maintains Target Price $45
A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $95
CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
CRISPR Technology Market Report 2024, With Profiles of Major Players Agilent Technologies, Beam Therapeutics, Caribou Biosciences, Crispr Therapeutics, Danaher, Genscript, Lonza and More - ResearchAndMarkets.com
RBC Capital Reiterates Sector Perform on CRISPR Therapeutics, Maintains $53 Price Target
A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $94
Oppenheimer Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)
Express News | CRISPR Therapeutics AG : Barclays Cuts Target Price to $55 From $59
Crispr Therapeutics AG: Hold Rating Amid Mixed Financial Performance and Clinical Developments
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Exact Sciences (EXAS) and Crispr Therapeutics AG (CRSP)
Crispr Therapeutics Price Target Maintained With a $84.00/Share by Needham
CRISPR Therapeutics Analyst Ratings
Barclays Remains a Hold on Crispr Therapeutics AG (CRSP)
Promising Pipeline and Successful Product Launches Boost Crispr Therapeutics' Buy Rating
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates
CRISPR Therapeutics | 10-Q: Q3 2024 Earnings Report
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Reports Q3 Revenue $602,000
Press Release: CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Crispr Therapeutics 3Q Loss/Shr $1.01 >CRSP